Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.
Andrew A. Lane, MD, PhD, director of the Blastic Plasmacytoid Dendritic Cell Neoplasm Center at Dana-Farber Cancer Institute and associate professor of medicine at Harvard Medical School, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs (Elzonris) for patients with blastic plasmacytoid dendritic cell neoplasms (BPDCN).
The phase 1/2 STML-401-0114 trial (NCT02113982) investigated the CD123-targeted cytotoxin tagraxofusp in patients with BPDCN, a rare myeloid malignancy. Multiple stages were used to assess the safety and efficacy of the drug. The first stage enrolled patients in a dose escalation cohort which determined the safety of a dose of 12 μg/kg once daily intravenously for days 1 through 5 of a 21-day-cycle.
This was followed by the pivotal stage that enrolled 47 patients with BPDCN, 32 of whom had no prior treatment and 15 of whom had been previously treated. The primary end point was the combined rate of complete response (CR) and clinical CR in treatment-naive patients, which was reached in 21 out of 32 patients (72%), leading to FDA approval.
This trial also included an expanded-access phase, Lane says. This stage presented results in July 2022, showing long-term safety and efficacy in 84 patients, 65 of whom were treatment naive. This included 19 first-line patients who had a CR or clinical CR and were then able to bridge to stem cell transplantation.
TRANSCRIPTION:
0:08 | Tagraxofusp, or Elzonris, or SL-401, was approved on the basis of a combined phase 1/2 trial, that by necessity, because of the rareness of the disease, was staged. The first stage of the trial enrolled patients in a dose-escalation safety goal to come to our go-ahead dose of 12 μg/kg per day for 5 days. That then was the dose that was tested in an expansion phase. And then we had a dedicated pivotal phase, which was to address the first-line treated patients for regulatory approval of the drug. Then that actually was even followed by an expanded-access phase. We reported in The New England Journal [of Medicine] a couple of years ago, a group of 47 patients, of which 32 were naive for treatment so first-line treated patients, and the rest were relapsed patients. And that formed the basis for the drug approval.
Understanding Risks and Training Needs for Outpatient Bispecific Usage
December 5th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Mancini, PharmD, BCOP, FHOPA, discussed the various approved bispecific T-cell engagers and gave guidance for healthcare professionals, patients, and caregivers related to adverse event management. This is the second of 2 articles based on this event.
Read More
FDA Clears IND for CT071 in RRMM and Primary Plasma Cell Leukemia
December 5th 2023CT071, a chimeric antigen receptor T-cell therapy candidate, had an investigational new drug application cleared by the FDA for patients with relapsed/refractory multiple myeloma and primary plasma cell leukemia.
Read More
Defining and Treating Classic Cases of Myeloproliferative Neoplasms
November 30th 2023In the first article of a 2-part series, Pankit Vachhani, MD, discusses what makes classical cases of myeloproliferative neoplasms unique and how ruxolitinib impacts their reduction of spleen volume.
Read More
Talquetamab Shows High Response Rates in BCMA-Pretreated RRMM
November 29th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, discussed results of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.
Read More